Tag:
Biologics
Latest Headlines
Latest Headlines
Bristol-Myers maps $250M manufacturing expansion to support growing R&D effort
Bristol-Myers Squibb--which startled the industry earlier this week with its plans to transition in a new R&D chief--has blueprinted a $250 million expansion of its biologics manufacturing facility in Devens, near I-495.
Conquering the complexities of biologics to get to biosimilars
By Eric Palmer
Ganesh Kaundinya, chief scientific officer at biologics and biosimilars developer Momenta Pharmaceuticals, doesn't mind a little regulatory uncertainty. For those responsible for mapping a manufacturing strategy for biosimilars, these uncertainties add to the pressure of an already complex and challenging endeavor. Read the report >>
Brought to you by CMC Biologics
Strides Arcolab puts biologics plant in Malaysia
Asia has become a center for biologics manufacturing, in part, because governments in the region are offering up deals to attract players. It is a trend that experts believe will lead to innovations that will lower costs for manufacturing both novel biologics and biosimilars. India's Strides Arcolab has decided to tap that trend and will build a new plant in Malaysia.
Kazakhstan government plans to build biologics plant
A number of drugmakers have targeted the central Asian country of Kazakhstan as a good arena in which to expand and now the government says it will get into the game as well.
Novartis blueprints $500M plant as pipeline fills with biologics
Novartis joins a growing number of drugmakers and contract manufacturers that see drugs based on cell cultures as one of the best bets of the future.
DSM snags project to feed Australian biologics plant
DSM Pharmaceutical Products has won another contract to feed the new biologics plant it is building with the help of government support in Australia.
MedImmune partners on trials for a new slate of cancer immunotherapy combos
Cancer immunotherapy research has once again topped the R&D charts as one of the hottest fields in biotech. And now MedImmune, the biologics arm of AstraZeneca, has teamed up with some prestigious research teams to come up with some revved up combo therapies using a few of their most promising antibodies.
Transgenic corn yields biotech drug for rare disease
Many biologics are notoriously expensive to produce, but genetically modified corn offers a potential alternative for producing complex protein drugs. And veteran Reuters scribe Ben Hirschler has chronicled one of the latest feats in "molecular farming," with scientists growing an enzyme drug for a rare genetic disease in transgenic corn.
UCB opens biologics plant in Belgium
Belgian drugmaker UCB Pharma has completed a €65 million ($84.8 million) biologics plant to take more control over the development and manufacturing of its biologics products.
Teva's Neupogen-knockoff approval highlights slow progress of biosims
The FDA has handed an approval to Teva for its biosimilar of the aging neutropenia drug Neupogen. But the significant barriers that lie between that treatment--tbo-filgrastim--and any kind of significant market share underscores just how slowly these new therapies will begin to reshape the U.S. drug market.
